

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problems Mailbox.**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification<sup>3</sup> :</b> <b>C12N 15/00; C07G 17/00</b> <b>C12P 19/34, 21/00, 21/00</b> <b>C12P 21/02; A61K 39/015</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 84/ 02917</b>  <b>(43) International Publication Date:</b> 2 August 1984 (02.08.84)
<b>(21) International Application Number:</b> PCT/AU84/00016 <b>(22) International Filing Date:</b> 27 January 1984 (27.01.84)  <b>(31) Priority Application Numbers:</b> PF 7843 PF 9788 <b>(32) Priority Dates:</b> 28 January 1983 (28.01.83) 10 June 1983 (10.06.83) <b>(33) Priority Country:</b> AU  <b>(71) Applicant (for all designated States except US):</b> THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RE- SEARCH [AU/AU]; Royal Parade, Parkville, VIC 3050 (AU).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> KEMP, David, James [AU/ AU]; 309 Belmore Road, North Balwyn, VIC 3103 (AU). ANDERS, Robin, Fredric [AU/AU]; 55 Brougham Street, North Melbourne, VIC 3051 (AU). COPPEL, Ross, Leon [AU/AU]; 6 Mercer Road, Armadale, VIC 3143 (AU). BROWN, Graham, Vallancey [AU/AU]; 35 Walsh Street, Balwyn, VIC 3103 (AU). SAINT, Robert, Bryce [AU/AU]; 2 Saville Court, Lower Templestowe, VIC 3107 (AU). COW- MAN, Alan, Frederick [AU/AU]; 3/20 Earl Street, North Carlton, VIC 3054 (AU). MITCHELL, Graham, Frank [AU/ AU]; 21 Sinclair Avenue, Lower Templestowe, VIC 3107 (AU).		<b>(74) Agents:</b> SLATTERY, John, Michael et al.; Davies & Collison, One Little Collins Street, Melbourne, VIC 3000 (AU).  <b>(81) Designated States:</b> BE (European patent), BR, CF (OAPI pa- tent), CG (OAPI patent), CH (European patent), CM (OAPI patent), DE (European patent), DK, FI, FR (European pa- tent), GA (OAPI patent), GB, GB (European patent), JP, MR (OAPI patent), NL (European patent), NO, SE (Euro- pean patent), SN (OAPI patent), TD (OAPI patent), TG (OAPI patent), US.  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> EXPRESSION OF PLASMODIUM FALCIPARUM POLYPEPTIDES FROM CLONED cDNA		
<b>(57) Abstract</b>  DNA molecules comprising artificially constructed polynucleotide sequences substantially corresponding to all or a portion of <i>Plasmodium falciparum</i> messenger RNA (mRNA) or genomic DNA (gDNA). Especially DNA molecules comprising artificially constructed polynucleotide sequences coding for the whole or part of one or more proteins occurring in <i>P. falciparum</i> , or a precursor or modification thereof. Such DNA molecules are capable of being expressed as a polypeptide(s). Synthetic peptides or polypeptides displaying the antigenicity of all or a portion of at least one <i>P. falciparum</i> antigen. Compositions for stimulating immune responses against <i>P. falciparum</i> antigens in a mammal, comprising at least one polypeptide displaying the antigenicity of a <i>P. falciparum</i> antigen, together with a pharmaceutically acceptable carrier therefor.		

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GA	Gabon	MR	Mauritania
AU	Australia	GB	United Kingdom	MW	Malawi
BB	Barbados	HU	Hungary	NL	Netherlands
BE	Belgium	IT	Italy	NO	Norway
BG	Bulgaria	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali		
FR	France				

"EXPRESSION OF PLASMODIUM FALCIPARUM POLYPEPTIDES  
FROM CLONED cDNA"

This invention relates to DNA molecules comprising artificially constructed polynucleotide sequences substantially corresponding to all or a portion of Plasmodium falciparum messenger RNA (mRNA) or genomic DNA (gDNA), in particular it relates to polynucleotide sequences coding for at least one protein or part thereof. The invention especially relates to DNA molecules comprising artificially constructed polynucleotide sequences coding for the whole or part of one or more proteins occurring in P. falciparum, or a precursor or modification thereof. Such DNA molecules are capable of being expressed as a polypeptide(s).

Of the four species of Plasmodium causing malaria in man, P. falciparum is the most important being a major cause of infant mortality in tropical countries. It has been estimated that in Africa alone malaria causes one million deaths each year and that world-wide 2,000 million people live in areas where there is the potential for transmission of malaria parasites. Immunity to malaria develops slowly so that recurrent infections cause significant morbidity in children living in endemic areas. Adults who have grown up in endemic areas will often have detectable



parasites in their blood but seldom suffer severe disease although malaria infection is a contributing cause to adult anaemia and may cause other serious illnesses.

5

In many countries malaria has become a more severe disease problem over the last decade. This is due to several factors which include the breakdown in malaria control programs, the emergence of insecticide resistance in the mosquito vectors and most importantly the emergence of strains of P. falciparum resistant to chloroquin, a key drug used in prevention and treatment of the infection.

10

P. falciparum is a single celled organism of the family, Plasmodiidae; order, Plasmodiida; subclass, Haemosporidia; subphylum, Sporozoa; and phylum, Protozoa. (Pathology of Protozoal and Helminthic Diseases. ed. R.A. Marcial-Rojas, Williams & Wilkins, Baltimore 1971)

15

Like other Plasmodia, P. falciparum has a complex life cycle. The infective stage to man (sporozoite) is injected into the blood when a female mosquito has a blood meal. Within minutes, sporozoites invade liver cells and within these cells undergo a stage of maturation and asexual multiplication resulting in the production of hundreds of merozoites from one sporozoite. Eventually the liver cell ruptures releasing merozoites which can then initiate a second asexual cycle in the blood by invading red blood cells (RBC).

20

25

30



As in the liver cell the parasite matures within the RBC and undergoes asexual multiplication to produce numerous merozoites which when released into the blood, upon rupture of the infected RBC, can  
5 invade another RBC and initiate another asexual cycle. For reasons that are not clearly understood, occasionally maturation within the RBC results in the formation of male or female gametes. When these sexual stages are ingested with a blood meal by a  
10 mosquito they fuse to initiate a process of sexual reproduction the end result of which is thousands of sporozoites in the salivary gland of the mosquito each capable of reinfecting a human being.

15 The immune response to malaria infection is complex. Both antibody and cell-mediated immune responses occur and responses are directed against components of several of the life cycle stages. The sera of putatively immune individuals contain  
20 antibodies recognizing over a hundred different polypeptide antigens in asexual blood stages of P. falciparum. Antibodies to asexual blood stage antigens do have anti-parasitic effects but which of the many specificities are host-protective is not  
25 firmly established.

There is a considerable body of evidence that indicates that the asexual blood stages of  
P.falciparum possess two types of antigens that may be  
30 targets of protective immune responses. Antigens of one type are common to all isolates of P.falciparum, thus immune responses with these specificities induced by infection with one isolate or strain of



P.falciparum will be equally effective against other isolates or strains. However, antigens of the other type vary in different isolates or strains of P.falciparum. Thus, host-protective immune responses directed against such antigens will be restricted in their efficacy. One or more of these responses of restricted specificity accounts for the observation that exposure to an isolate of P.falciparum provides better protection against challenge with the homologous isolate than with heterologous isolates.

A system for the continuous culture of the asexual blood forms of P. falciparum in vitro is available, however, it will not be feasible to produce sufficient amounts of the appropriate antigens required for a vaccine from cultured parasites. Furthermore, parasites are grown in vitro in human RBCs and in a medium supplemented with human serum thus it would be difficult to ensure parasite antigens derived from cultures were free of human antigens which may induce autoimmunity in immunised individuals.

Using the techniques developed over the last ten years it is now possible to introduce the DNA (deoxyribonucleic acid) coding for non-bacterial proteins into bacterial cells via the intermediary of a plasmid or bacteriophage, (see for example Burrell, C.J. et al, Nature, 279, 43-47, 1979.). In general the construction of the recombinant DNA molecules comprises the steps of deriving the DNA template coding for the desired protein from the non-bacterial



parent and inserting this piece of heterologous DNA into a cloning vehicle, such as a bacteriophage, and then infecting an appropriate bacterial host with the modified bacteriophage. A general discussion of the manipulation of genes leading to the formation of recombinant DNA was published by S. Cohen in Scientific American, 233, 24-33, 1975.

Many non-bacterial genes have been inserted and multiplied within bacteria such as Escherichia coli, and many non-bacterial proteins have been expressed by bacteria using recombinant DNA technology, including the haemagglutinin of influenza viruses (Porter, A.G. et al, Nature, 282, 471-477, 1979) the hepatitis B virus protein (Burrell, C.J. et al, 1979, loc. cit.), and mouse immunoglobulin heavy chains (Kemp, D.J. & Cowman, A.F., Proc. Nat. Acad. Sci. U.S.A., 1981, 78, 4520-4524). Notwithstanding the considerable amount of work carried out in recent years on recombinant DNA research, there has been a paucity of results amenable to immediate and practical application in the field of recombinant DNA involving the manipulation of protozoan genetic material.

One approach to the production of vaccines for inducing immunity against Plasmodia antigens, disclosed in European Patent Applications Nos. 0062924 and 0071705, both in the name of The Wellcome Foundation Limited, has been based on the use of monoclonal antibodies to define certain antigens by molecular weight and immunofluorescence staining pattern, and to isolate these antigens for use in immunisation. The present invention, however, is





based on an entirely different approach in using recombinant DNA techniques in the production of antigenic polypeptides.

5           The present invention provides for the synthesis of individual polypeptides substantially equivalent to naturally occurring Plasmodium proteins, in particular P. falciparum proteins recognised as antigens by defined sera. In one particular embodiment, this  
10          invention provides for the synthesis of polypeptides substantially equivalent to a family of Plasmodium antigens referred to as S antigens. S antigens are found in the sera of patients during the acute phase of a malaria infection and are also released into the  
15          medium when P.falciparum is cultured in vitro. Different isolates of P.falciparum are characterised by S antigens that may vary in antigenicity and molecular weight. Immune responses directed against S  
20          antigens may be one component of the host-protective isolate-restricted immunity referred to above. In a second embodiment, this invention provides for the synthesis of other polypeptides which are common to all isolates of P.falciparum and may therefore stimulate immune responses which are host-protective  
25          against all isolates.

          The invention also provides for the synthesis of P. falciparum polypeptides either as individual entities or as fusion products of two or more  
30          polypeptide portions. In addition the present invention provides the means whereby the concurrent synthesis of immunogenic proteins normally encoded for



by different variants of P. falciparum may be effected.

5 According to one aspect of the present invention, there is provided a DNA molecule comprising a nucleotide sequence substantially corresponding to all or a portion of P. falciparum RNA. Preferably, the nucleotide sequence codes for at least one polypeptide of P. falciparum. Such a DNA molecule is capable of  
10 being expressed as a polypeptide recognizable as substantially corresponding to a P. falciparum protein. In one particular aspect of the invention, the DNA molecule is capable of being expressed as a polypeptide recognisable as substantially  
15 corresponding to S antigen by its antigenic relationship to the S antigen released into culture supernatants by P.falciparum strains.

In an alternative embodiment, the nucleotide  
20 sequence may code for all or a portion of at least two P. falciparum polypeptides each derived from a different isolate, strain or variant of P. falciparum.

By way of exemplification of this aspect of the  
25 invention, the polynucleotide sequences may be characterised by at least a portion thereof having one of the partial base sequences substantially as shown in Figures 1 and 2 hereinafter. The particular sequence shown in Figure 1 has been identified as  
30 corresponding to a portion of the S antigen of P.falciparum FC27. The particular sequence shown in Figure 2 is capable of being expressed as a polypeptide with a relative molecular mass (Mr) of



140,000 which is common to all isolates of P.falciparum and is apparently, but not exclusively, located on the membrane of newly invaded red blood cells.

5           It will be appreciated that the polynucleotide sequences of this aspect of the invention may be obtained from natural, synthetic or semi-synthetic sources; furthermore, these polynucleotide sequences may be naturally-occurring sequences, or they may be  
10   related by mutation, including single or multiple base substitutions, deletions, insertions and inversions, to such naturally-occurring sequences, provided always that the DNA molecule comprising such a sequence is  
15   capable of being expressed as a polypeptide displaying the antigenicity of one or more antigens of P.falciparum.

          The nucleotide sequence may have expression control sequences positioned adjacent to it, such  
20   control sequences being derived either from P.falciparum nucleic acid or from a heterologous source.

          This invention also provides a recombinant DNA  
25   molecule comprising an expression control sequence having promoter sequences and initiator sequences as herein defined, and a nucleotide sequence substantially coding for all or part of at least one  
30   protein of P. falciparum, the nucleotide sequence being located 3' to the promoter and initiator sequences.



In yet another aspect, the invention provides a recombinant DNA cloning vehicle capable of expressing all or part of at least one protein of P. falciparum, comprising an expression control sequence having promoter sequences and initiator sequences, and a nucleotide sequence substantially coding for all or part of at least one protein of P. falciparum, the nucleotide sequence being located 3' to the promoter and initiator sequences.

In a further aspect, there is provided a host cell containing a recombinant DNA cloning vehicle and/or a recombinant DNA molecule as described above.

In yet further aspects, there are provided fused polypeptides comprising polypeptide sequences displaying P. falciparum antigenicity as the C-terminal sequence, and an additional polypeptide, for example a polypeptide coded for by the DNA of a cloning vehicle, as the N-terminal sequence fused thereto. Such a fused polypeptide can be produced by a host cell transformed or infected with a recombinant DNA cloning vehicle as described above, and it can be subsequently isolated from the host cell to provide the fused polypeptide substantially free of other host cell proteins.

The present invention also extends to synthetic peptides or polypeptides displaying the antigenicity of all or a portion of at least one antigen of P. falciparum. As used herein, the term "synthetic" means that the peptides or polypeptides have been produced by chemical or biological means, such as by



means of chemical synthesis or by recombinant DNA techniques leading to biological synthesis. Such polypeptides can, of course, be obtained by cleavage of a fused polypeptide as described above and  
5 separation of the desired polypeptide from the additional polypeptide coded for by the DNA of the cloning vehicle by methods well known in the art. Alternatively, once the amino acid sequence of the desired polypeptide has been established, for example,  
10 by determination of the nucleotide sequence coding for the desired polypeptide, the polypeptide may be produced synthetically, for example by the well-known Merrifield solid-phase synthesis procedure [A.Marglin and R.B.Merrifield, Annu. Rev. Biochem. 39, 841  
15 (1970)].

It will be appreciated that polypeptide sequences displaying antigenicity characteristic of antigens of P.falciparum will have utility in serological  
20 diagnosis, and in the preparation of single or multivalent vaccines against P.falciparum by methods well known in the art of vaccine manufacture.

25 The invention further provides a method of preparing a DNA molecule substantially coding for at least one polypeptide of P. falciparum comprising:

- 30 (a) isolating P. falciparum single stranded RNA;
- (b) preparing a first single strand of DNA complementary to the single strand of P. falciparum RNA;



(c) preparing a second single strand of DNA complementary to and hydrogen bonded to the first DNA strand so as to produce a double strand of DNA.

5

The double strand of DNA so produced can be inserted into a cloning vehicle following digestion of the cloning vehicle with a restriction endonuclease, free ends of the cloning vehicle being joined to the DNA molecule so as to form a recombinant cloning vehicle. This in turn can be inserted into a suitable host cell by for example transformation or infection.

It will be appreciated also that the P. falciparum DNA inserted into the cloning vehicle and encoding polynucleotide sequences capable of being expressed as a polypeptide displaying antigenicity of one or more antigens of P. falciparum may be derived from chromosomal DNA of P. falciparum by digesting such DNA with an appropriate restriction endonuclease.

As used herein the terms listed below have the following meanings:-

Nucleotide: a unit of DNA or RNA comprising a sugar moiety (pentose), a phosphate and a nitrogenous heterocyclic base. The base is joined to the sugar moiety via the glycosidic carbon (1' carbon of the pentose) and the base characterizes the nucleotide. The four DNA bases are adenine (A), guanine (G), cytosine (C) and thymine (T). The four RNA bases are A, G, C and uracil (U).



Recombinant DNA: - a hybrid double stranded DNA sequence comprising at least two double stranded DNA nucleotide sequences, the first sequence not being found together in nature with the second sequence.

5

Cloning Vehicle:- non-chromosomal double stranded DNA capable of replicating when placed within a unicellular micro-organism.

10

Bacteriophage:- a cloning vehicle derived from viruses or bacteria which may infect certain strains of bacteria.

15

Plasmid:- a cloning vehicle derived from viruses or bacteria.

20

Structural Gene:- a sequence of DNA nucleotides which codes for a sequence of amino acids characteristic of a specific polypeptide.

Promoter Sequences:- sequences of DNA nucleotides which control the initiation, rate or magnitude of transcription.

25

Initiator Sequences:- sequences of DNA nucleotides which control the initiation of transcription.

30

Transcription:- the process whereby RNA polymerase is caused to move along the DNA sequence forming messenger RNA.

Translation:- the process of producing a polypeptide from messenger RNA.



Operon:- a structural gene(s) coding for polypeptide expression which is preceded by initiator sequences.

5     Expression:- the process involved in producing a polypeptide from a structural gene

Lysogeny:- the integration of bacteriophage nucleotide sequences into a bacterial genome.

10         The invention will be further described by way of reference to the accompanying diagrams, in which:

15         Figure 1 shows the nucleotide and corresponding amino acid sequence of a clone numbered as Ag16 which corresponds to the S antigen of isolate FC27.

20         Figure 2 shows a partial sequence of a clone numbered as Ag13 - the sequence has been arranged to show that this clone contains both 24 base repeats (8 amino acids) and 12 base repeats (4 amino acids).

25         Figure 3 is a schematic diagram of the construction of a bacteriophage vector and library from P. falciparum and expression of the polypeptides derived therefrom;

30         Figure 4 shows the detection with human immune sera of recombinant E. coli clones which are expressing polypeptides displaying P. falciparum antigenicity;

Figure 5 shows (A) a secondary screen using human immune sera of the positive clones selected in Figure





3, compared with (B) hybridization of  $^{32}\text{P}$  labelled cDNA from P. falciparum mRNA to a duplicate set of the same clones; and

5           Figure 6 shows the detection of the fused P. falciparum -  $\beta$ -galactosidase polypeptides by Coomassi staining (A), with anti- $\beta$ -galactosidase antibodies (B) and also with human antibodies to malaria antigens (C).

10

          Figure 7 shows an analysis by one-dimensional polyacrylamide gel electrophoresis of the protein composition of the clone (identified as clone Ag16 and containing the recombinant phage  $\lambda$ Amp3-Ag16) expressing a polypeptide antigenically related to the S antigen of isolate FC27 (lane 2). The analysis of the semi-purified protein obtained by fractionating the insoluble pellet (lane 3) obtained from a bacterial lysate on Sepharose CL6B in the presence of 0.1% sodium dodecyl sulphate and 1 mM dithiothreitol is illustrated in lane 4. For comparison, lane 1 shows the analysis of the protein composition of a bacterial clone containing non-recombinant phage.

20

25           Figure 8 shows the detection of clone Ag16 with antiserum from a rabbit immunized with fusion protein of the clone Ag16. From a total of 78 antigen-positive clones on the same filter, clone Ag16 specifically reacts with the antiserum. This indicates that immunizing a rabbit with the fusion protein from clone Ag16 has induced antibodies to the P.falciparum component of the fusion protein.

30



Figure 9 shows in Panel A the detection of S antigens in the culture supernatants of P.falciparum isolate FC27 (lane 1) and cloned parasite line E12 (lane 2) with Papua New Guinea (PNG) serum containing antibodies to S antigens. The identical antigens are detected with antiserum from a rabbit immunized with fusion protein of the clone Ag16 (Panel B).

Figure 10 (A to E) shows the specific staining of mature P.falciparum parasites when the rabbit antiserum prepared against the fusion protein from clone Ag16 is used in indirect immunofluorescence.

Figures 11 - 14 show the specific staining of P.falciparum blood-stage parasites when indirect immunofluorescence is performed using antisera prepared against clones Ag13, Ag23, Ag63 and Ag144 respectively.

#### General Approach

A variety of techniques are available for preparing the recombinant DNA molecule according to the invention, one of which comprises the steps of synthesising a single stranded DNA copy (cDNA) of the RNA purified from an isolate of whole P. falciparum using a reverse transcriptase enzyme. After the original RNA strand has been degraded the cDNA is converted into a double strand (ds cDNA), which is then treated to remove any loops of DNA which have formed using, for example, a nuclease enzyme. An alternative method of preparing the double stranded



cdNA is via chemical synthesis using techniques well known in the art.

5       Once the double stranded cdNA has been produced  
the next step is to insert it into a cloning vehicle,  
which may be for example a bacterial plasmid or  
bacteriophage. This may be achieved by first cleaving  
the DNA of the purified cloning vehicle, for example  
λAmp 3 (described hereinafter), using a restriction  
10       endonuclease enzyme such as EcoRI, which cleaves the  
DNA at sites where complementary nucleotides are  
arranged in rotational symmetry. The double stranded  
P. falciparum cdNA can then be inserted between and  
linked to the open ends of the cloning vehicle by  
15       joining synthetic oligonucleotides to blunt ended ds  
cdNA and making the new termini cohesive by either  
exonuclease or endonuclease digestion, prior to  
ligation with appropriately linearized cloning  
vehicle. Alternatively, other techniques well known  
20       in the art may be used.

Once the double stranded P. falciparum cdNA has been  
annealed with the DNA of the cloning vehicle, an  
appropriate host, such as a bacterium, is transformed,  
25       infected or lysogenized with the recombinant cloning  
vehicle, so as to permit that host to express the P.  
falciparum ds cdNA, and thereby produce a polypeptide  
or polypeptides which may display P. falciparum  
antigenicity.

30

There are several host-cloning vehicle  
combinations that could be used for the expression of  
P. falciparum polypeptides. For example useful



cloning vehicles include bacterial plasmids such as pAT 153, (Twigg, A.J. Nature, 283, 216-218, 1980) pBR 322, (Sutcliffe, J. G. Cold Spring Harbour Symposium for Quantitative Biology, 43, 77-90, 1978) other E. coli plasmids and wider host range plasmids. Bacteriophages such as the many derivatives of phage  $\lambda$ , and particularly  $\lambda$ Amp 3, may also be suitable. Hosts that may be used include bacteria such as strains of E. coli K. 12, e.g. E. coli HB101, (Boyer, H. W. et al, J. Mol. Biol., 41, 459-472, 1969) E. coli  $\lambda$ 1776, (Curtiss, R. et al, Ann Report Dep. of Microbiology University of Alabama, 1976, 96-106) E. coli  $\lambda$ 2282 and E. coli MRC1, strains of Bacillus subtilis and Pseudomonas, as well as yeasts and other fungi, and other unicellular organisms. Alternatively, eucaryotic cells such as mammalian cells may be used. It is only to be expected, however, that not all hosts will be equally effective.

Within each cloning vehicle, various sites may be available for insertion of the P. falciparum ds cDNA, each site being designated by the restriction endonuclease enzyme which cleaves DNA. Thus, for example, enzyme EcoRI cleaves bacteriophage  $\lambda$ Amp 3 in the gene coding for  $\beta$ -galactosidase.

The selection of the site on the cloning vehicle for insertion of P. falciparum ds cDNA may be governed by a variety of factors, for example size of polypeptide to be expressed and location of promoter and initiator sequences. Consequently not all sites may be equally effective for a given polypeptide.



It is essential that the P. falciparum ds cDNA inserted into the cloning vehicle can be read in the correct phase. In order to achieve this it may be necessary to insert supplementary nucleotides for example between the start points of transcription and translation of the P. falciparum ds cDNA fragment whose expression is desired. Addition of such nucleotides must not, of course, form a nucleotide sequence that could interrupt translation.

Expression of P. falciparum ds cDNA, which has been inserted into a cloning vehicle, which in turn has been used to transform, infect or lysogenize a suitable host cell, may be detected by the appearance of a function specific for the protein, that is, immunological activity in the case of P. falciparum. Several methods are available, for example the essentially immunological colony screening method disclosed by D. J. Kemp and A. F. Cowman in Proc Nat. Acad. Sci. USA, 1981, 78, 4520-4525. One alternative technique is to inject into a laboratory animal the crude bacterial extract or purified fused polypeptide derived from a culture of bacteria transformed with an appropriately engineered cloning vehicle and to test for the formation of appropriate antibodies. A second alternative is to perform an immunoprecipitation of a crude extract of the bacterial cells. Yet a further method is the "Maxicell Technique" described by Sancar et al in J. Bact., 1979, 137, 692-693.

The nature of the polypeptide produced as a result of expression by the host of the recombinant DNA molecule of the invention will depend on the point



of insertion into the DNA of the cloning vehicle, so that in practice a fused polypeptide may be formed which comprises a polypeptide coded for by P. falciparum ds cDNA and an additional polypeptide coded for by the DNA of the cloning vehicle. Thus, for example, if the bacteriophage  $\lambda$  Amp 3 is cleaved by EcoRI a fused polypeptide comprising a portion of the  $\beta$ -galactosidase enzyme and the polypeptide coded for by the P. falciparum ds cDNA may be expressed. The fused polypeptide may then be selectively cleaved so as to separate the desired P. falciparum polypeptide from the superfluous amino acid sequence. Cleavage may be effected outside the host following harvest of the microbial culture by techniques well known to those skilled in the art. Cleavage may be necessary in order that the P. falciparum expression product can exert the desired antigenic activity, however during harvest of the microbial culture the fact that a superfluous amino acid sequence is linked to the required P. falciparum polypeptide may help to prevent degradation of the expression product by endogenous enzymes. Alternatively cleavage may be effected within the host, this may be achieved by inserting into the cloning vehicle, DNA coding for the desired cleavage enzymes.

The production of a fusion product of a polypeptide coded for by P. falciparum ds cDNA and a portion of for example  $\beta$ -galactosidase enzyme may increase the stability of the hybrid protein in E. coli and even enhance the immunogenicity of the P. falciparum protein.



Alternatively, appropriate nucleotide sequences, derived for example from P. falciparum RNA, may be inserted before the P. falciparum ds cDNA so as to ensure that the P. falciparum ds cDNA can be expressed  
5 alone, and not as a fusion product with a host polypeptide.

Once host cells or recombinant DNA cloning vehicles containing at least some P. falciparum ds  
10 cDNA have been identified, as explained above, the recombinant cloning vehicle DNA may be purified and then analysed in order to determine how much of the P. falciparum ds cDNA has been inserted. In order to do  
15 this the recombinant cloning vehicle DNA is treated with several different restriction endonucleases, for example Eco RI, Pst I, Sal I, Bgl II, Bam HI, Hind III and Hinf I, and the digestion products may be analysed  
20 by gel electrophoresis, followed by sequencing of the fragments using the method described by Maxam and Gilbert in Proc. Nat. Acad. Sci. USA, 1977, 74, 560-564.

The various DNA molecules may be useful as a probe for the in vitro diagnosis of the presence in  
25 biological samples of P. falciparum, and in particular may be used to define the isolate causing an outbreak of malaria. For this purpose the DNA molecules may be labelled, in known manner, with a radioactive isotope.

30 Once recombinant DNA cloning vehicles expressing polypeptides corresponding to natural P.falciparum immunogens have been identified, the expressed polypeptides synthesized by these cloning vehicles,



for example, as a fusion protein with  $\beta$ -galactosidase, can be isolated substantially free of contaminating host cell components by techniques well known to those skilled in the prior art.

5

Isolated proteins containing, in part, amino acid sequences corresponding to a portion or all of a natural immunogen of P.falciparum may be used to raise monospecific but polyclonal antisera by immunizing rabbits, mice or other animals using well established procedures.

10

In addition the expression product of the recombinant cloning vehicle may be used for serological diagnosis and in the preparation of single or multivalent vaccines against P. falciparum by methods well known in the art of vaccine manufacture. Such vaccines are effective in stimulating antibodies in vaccinated animals and thereby protecting against plasmodia.

20

Traditional vaccine formulations may comprise the antigenic polypeptides together with known adjuvants such as aluminium hydroxide, in association with a pharmaceutically acceptable carrier. Suitable carriers include liquid media such as saline solution appropriate for use as vehicles to introduce the polypeptides into a patient.

25

An alternative vaccine formulation may comprise a virus or microorganism in association with a pharmaceutically acceptable carrier, the virus or microorganism having inserted therein a DNA molecule

30





according to this invention for stimulation of an immune response directed against polypeptides encoded by the inserted DNA molecule.

Further characteristics and features of the invention are described in the following Examples which are presented by way of illustration only and are not to be considered as limiting the scope of the present invention in any way.

EXAMPLE 1      The Production of cDNA Clones which  
Express Natural Immunogens of  
P.falicparum.

Reagents.

DNA polymerase I, EcoRI, and XbaI from Boehringer Mannheim GmbH. EcoRI methylase, BstNI, exonucleases Bal 31 and S1, calf intestinal phosphatase and T4 ligase were from New England Biolabs, Bethesda, Md. Reverse transcriptase was the gift of J. Beard, Life Sciences Inc., St. Petersburg, Fla. EcoRI linkers (CGGAATTC) were from New England Biolabs, XbaI linkers (CTCTAGAG) were from Amersham, England.  $\beta$ -galactosidase (chromatographically purified) was from P. L. Biochemicals Inc., Milwaukee, Wis.

Strains.

Bacteriophage strains  $\lambda$ gt11 and E.coli strains RY1073, and RY1082 were the generous gifts of T. Huynh, R. Young and R. Davis (Stanford).



P. falciparum mRNA.

5        P. falciparum isolate FCQ27/PNG (FC27) obtained  
from the Madang area of Papua New Guinea was cultured  
in vitro (Chan, P. et al SE Asian J Trop. Med. Public  
Health 11:435-440 1980). Enriched parasite  
preparations were prepared by lysis of the  
erythrocytes with Saponin (Zuckerman, A. et al Bull  
W.H.O. 37:431-436 1967). RNA was prepared from them  
10      and poly A<sup>+</sup> RNA selected by oligo dT cellulose  
chromatography.

Enzyme reactions.

15        The procedures were as in Maniatis et al  
"Molecular Cloning", Cold Spring Harbour, 1982.

Construction of cDNA clones in  $\lambda$ gt10.

20        mRNA (~1 $\mu$ g) was copied into cDNA with reverse  
transcriptase and double-stranded cDNA was then  
prepared with DNA polymerase I. After treatment with  
nuclease S1 the ds cDNA was methylated with EcoRI  
methylase and ligated to 0.5  $\mu$ g of phosphorylated  
25      EcoRI linkers with T4 ligase. The mixture was then  
treated with 20 units of EcoRI for 90 min. at 37° and  
fractionated by electrophoresis on a 1% agarose gel in  
50mM Tris, 20 mM NaOAc 2mM EDTA pH 8.2. DNA between  
0.6 and 2.0 kb was recovered by electrophoresis on to  
30      Schleicher and Schuel NA45 membrane filter and elution  
in 1M NaCl, 50mM free base arginine at 70°C for 1 hr  
followed by ethanol precipitation and aliquots (20 ng)  
were ligated to EcoRI-cleaved  $\lambda$ gt10 DNA (1  $\mu$ g),



packaged into phage and plated on E. coli RY1073  
(Young R, and Davis R, Proc. Natl. Acad. Sci. USA, in  
press). About  $2 \times 10^5$  recombinants were obtained, and  
~40% of these hybridized detectably to  $^{32}\text{P}$ -cDNA from  
5 P. falciparum.

#### Construction of Amp3.

DNA (5  $\mu\text{g}$ ) from pBR322 was cleaved with EcoRI and  
10 BstNI. After treatment with 0.3 units of exonuclease  
Bal31 for 30 sec the DNA was ligated to Xba linkers as  
above, cleaved with 100 units of XbaI and fractionated  
on a 1% agarose gel. The ~1.7kb fragment was  
recovered and ligated to 1  $\mu\text{g}$  of XbaI cleaved gtl1  
15 (Young, R. and Davis, R. Proc. Natl. Acad. Sci. USA,  
in press) DNA and packaged as above. E. coli RY1082  
was infected with the phage and plated on L plates  
containing ampicillin (30  $\mu\text{g}/\text{ml}$ ). An Amp R colony was  
chosen and shown to be lysogenic for a  $\text{lac}^+$ ,  
20 temperature sensitive phage (designated  $\lambda\text{Amp3}$ )  
identical to  $\lambda\text{gt11}$  except that it contained a ~1.7 kb  
fragment inserted into the XbaI site.

#### Insertion of cDNA from $\lambda\text{gt10}$ into $\lambda\text{Amp3}$ .

25 DNA (500  $\mu\text{g}$ ) prepared from plate stocks of the  
 $\lambda\text{gt10}$ -cDNA library grown on E. coli ( $600 \text{ r}_k^-, \text{m}_k^+$ ) was  
cleaved with EcoRI (1000 units) for 2 hrs at  $37^\circ$  and  
1/50 of the total was labelled with  $^{32}\text{P}$ -dATP and the  
30 Klenow fragment of DNA polymerase I. After phenol  
extraction, the labelled and unlabelled DNAs were  
mixed and centrifuged for 18 hr at 37,000 RPM on a  
10-40% glycerol gradient in 10mM Tris/HCl pH 7.4, 1mM



EDTA and 300 mM NaOAc. The cDNA fragments were detected as a radioactive peak well separated from the vector fragments and recovered by ethanol precipitation.

5

Uncut  $\lambda$ Amp3 DNA (50  $\mu$ g in 100  $\mu$ l) was ligated for 4 hr at 15° to seal and protect the cohesive ends from subsequent phosphatase treatment. The ligase was then inactivated at 70° for 10 min, NaCl and Tris/HCl pH 7.4 were added to 50mM and 100mM and the DNA cleaved with EcoRI (500 units) for 4hr. The DNA was treated with calf intestinal phosphatase (0.02 units), phenol extracted and ethanol precipitated. Aliquots (1 $\mu$ g) were ligated for 16 hr at 15° to a 4 fold molar excess of the inserts from the  $\lambda$ gt10 library in a 10  $\mu$ l system and packaged as above. E. coli RY1082 was then infected with phage in the packaging mix for 30 min at 30°, incubated at 30° for a further 30 min after adding L broth (1 ml) to allow expression of  $\beta$  lactamase and plated on nitrocellulose filters on L plates containing 30  $\mu$ g/ml ampicillin at 30°. Approximately  $5 \times 10^4$  Amp R colonies were obtained from 6  $\mu$ g vector.

25 Screening of the  $\lambda$ Amp3 - P. falciparum cDNA library with antibodies to P. falciparum.

Colonies were replicated to nitrocellulose filters [Hanahan, D. and Meselson, M. Gene 10, 63-67 (1980)] grown for 1-2 hr at 30° on CY plates containing 30  $\mu$ g/ml ampicillin and induced at 42° for 1.5 hr. The colonies were lysed by placing the filters on 3MM paper saturated with 1% NaDodSO<sub>4</sub> in H<sub>2</sub>O

30



for 15 min and then moved into an atmosphere saturated with  $\text{CHCl}_3$  for a further 15 min. The filters were washed by rocking in 10mM Tris-HCl, 0.15M NaCl, pH8.4, 3% bovine serum albumin (BSA) for 2 hr and then  
5 Tris:NaCl alone for 1 hr at room temperature. They were then treated with affinity purified antibodies to P. falciparum (25  $\mu\text{g/ml}$ ) in BSA:Tris:NaCl for 2 hr, washed twice in Tris:NaCl and twice in Tris:NaCl containing 0.05% Triton X-100, treated with  
10  $^{125}\text{I}$ -labelled protein A from S.aureus (40  $\mu\text{Ci}/\mu\text{g}$ ; 0.4  $\mu\text{Ci/ml}$ ) in BSA:Tris:NaCl for 1 hr, washed, dried and auto-radiographed with an intensifying screen for 16 hr.

15 Preparation and purification of sera.

Serum was collected with informed consent from adults free of P. falciparum in the endemic Madang area of Papua New Guinea. IgG isolated on Protein  
20 A-Sepharose from each serum was tested for inhibition of growth of P. falciparum in vitro (Brown, G.V. et al, Infect. Immun. 39: in press 1983) and five inhibitory sera were pooled. The antibodies were purified by two cycles of absorption of P. falciparum  
25 (isolate FC27) proteins bound to CNBr-activated Sepharose. Saponin enriched parasites were sonicated in PBS and centrifuged at 2,000g for 10 min. The supernatant was adjusted to approximately 20mg/ml with PBS and conjugated to CNBr-Sepharose. Bound  
30 antibodies were eluted with 0.1M glycine, 0.15M NaCl, pH 2.6 and immediately adjusted to pH 7.4 with 2M Tris-HCl pH7.4.



Analysis of proteins by Western Blotting

Protein extracts of induced  $\lambda$ Amp3 - P. falciparum clones were prepared and fractionated on 7.5% acrylamide NaDodSO<sub>4</sub> gels. Proteins from the gels transferred electrophoretically to nitrocellulose and incubated at room temperature in BSA:Tris:NaCl 1 hr before reaction for 90 min with rabbit anti- $\beta$ -galactosidase or anti-malaria antibodies. Antibodies to E. coli in both reagents were removed by incubating 100  $\mu$ l of rabbit serum or 0.5 to 1.0 mg of human IgG with 1 ml of sonicate of  $\lambda$ Amp3 infected E. coli for 1 hr at 4°C, followed by centrifugation (12,000g, 10 min) and the supernatant diluted with BSA:Tris:NaCl to 50 ml. The nitrocellulose sheets were then washed, reacted with <sup>125</sup>I-labelled protein A, rewashed and autoradiographed as above. Rabbit antiserum to  $\beta$ -galactosidase was prepared with commercially available enzyme (P-L Biochemicals Inc., lot 535-3). Injection of 0.5 mg  $\beta$ -galactosidase in complete Freund's adjuvant (subcutaneously and intramuscularly) was followed at 4 week intervals by 0.5 mg in incomplete Freund's adjuvant. Serum collected 2 weeks after the last injection was used after absorbing out antibodies to antigens in E. coli RY1082 as above.

RESULTS AND DISCUSSIONS

Our strategy for construction of an expression library from P. falciparum mRNA, based on the  $\lambda$ gt11 expression system of Young and Davis is shown in Fig. 3. cDNA cloned into the unique EcoR1 site near the 3'



end of the  $\beta$ -galactosidase gene of  $\lambda$ gt11 can be expressed as polypeptides fused to  $\beta$ -galactosidase. E. coli colonies lysogenic for the temperature sensitive recombinants can then be grown at the permissive temperature followed by induction of the phage at 42° to achieve high levels of expression. High-frequency-lysogeny E. coli strains were employed to ensure that most colonies obtained after infection with phage are lysogens. However, a significant proportion of the colonies are always non-lysogens which being lac<sup>-</sup>, are difficult to distinguish from recombinant lysogens. We introduced the  $\beta$ -lactamase gene from pBR322 into  $\lambda$ gt11 (see Fig. 3 and Materials and Methods), generating a phage designated  $\lambda$ Amp3. Lysogens of  $\lambda$ Amp3-cDNA give amp<sup>R</sup>-lac<sup>-</sup> colonies readily distinguishable from parental amp<sup>R</sup>-lac<sup>+</sup> colonies on plates containing ampicillin and 5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactoside, while non-lysogens are killed. Further,  $\lambda$ Amp3 lysogens can be directly selected from cells infected with phage from a packaging reaction, eliminating the need to amplify a phage stock.

To prevent religated parental molecules predominating in our library the EcoRI-cut  $\lambda$ Amp3 vector was treated with phosphatase. Because this markedly reduced the cloning efficiency, we first amplified the cDNA by cloning it into the phage vector  $\lambda$ gt10 (Fig.3). DNA from the  $\lambda$ gt10-cDNA phage pool was cleaved with EcoRI and the released cDNA was isolated and ligated to phosphatase-treated EcoRI cleaved  $\lambda$ AMP3 DNA to generate the final expression library. This procedure resulted in a library of  $\sim 5 \times 10^4$  lysogenic



Amp R colonies of which  $\geq 98\%$  were  $\text{lac}^-$  and  $>50\%$  hybridized detectably to  $^{32}\text{P}$  cDNA from P. falciparum.

5     Identification of E. coli colonies which express P. falciparum antigens

10     To detect colonies expressing antigens of P. falciparum we lysed induced colonies in situ with  $\text{NaDodSO}_4$  and chloroform vapour under conditions which allow binding of proteins directly to the nitrocellulose. After treatment with BSA the filters were treated with antibodies followed by  $^{125}\text{I}$ -labelled protein A from S. aureus which binds to antibodies localized at the site of a colony. Similar procedures  
15     have recently been described.

20     Antibodies from immune individuals in the endemic Madang area of Papua New Guinea were used to detect P. falciparum antigens. The IgG fractions of the individual sera which inhibited growth of P. falciparum in vitro were pooled. The IgG pool contained antibodies against many P. falciparum proteins, but also reacted strongly with E. coli, necessitating enrichment of the antibodies by affinity  
25     chromatography on P. falciparum proteins and depletion of the anti E. coli activity (Materials and Methods).

30     The result of such a screen on a filter containing about  $10^3$   $\lambda\text{Amp3-cDNA}$  colonies is shown in Fig. 4. Several colonies have apparently reacted with the IgG, giving signals of varying intensity. No such variation is seen with normal IgG although both IgGs give a background reaction with all colonies. Clones





in the area of the signals (generally 3-10 colonies) were plated for single colonies and picked at random in triplicate, so that some should be positive with the remainder providing negative controls. A significant proportion again reacted with the immune IgG but not with normal IgG. The signals were reproducible in the triplicates and the intensity of positive signals in any row (all of which derive from the same original positive) was characteristic.

The antigen-positive colonies contain P. falciparum cDNA sequences

We tested a replica of the colonies shown in Fig 5A by colony hybridization with  $^{32}\text{P}$  cDNA to establish whether the positive clones contained P. falciparum cDNA sequences. All of the antigen-positive clones hybridized (Fig. 5B). The extent varied markedly and there was no relationship between the extents of immunological reactivity and hybridization. Most appear to be derived from mRNAs of moderate abundance. The differences in extent of hybridization indicates that the positive colonies derive from different mRNAs.

P. falciparum antigens expressed as polypeptides fused to  $\beta$ -galactosidase.

We examined proteins from lysates of induced antigen-positive and negative clones by gel electrophoresis. Staining with Coomassie blue revealed that some clones, both antigen-positive and negative, produced abundant quantities of unique



polypeptides larger than  $\beta$ -galactosidase (e.g. clones Ag13, Ag23 and C9 in Fig. 6). When the proteins were transferred from gels to nitrocellulose by the "Western blotting" procedure and scored with anti- $\beta$ -galactosidase serum, these unique large polypeptides all reacted strongly (Fig. 6). Polypeptides of lower molecular weight were also evident. These may be degradation products or they may be generated by internal initiation or premature termination.

When Western blots were scored with the affinity-purified anti-P. falciparum IgG, the results fell into 3 classes (Fig. 6). Firstly, the large polypeptide in clone Ag13 reacted strongly, demonstrating that it contains a P. falciparum antigen sequence as well as  $\beta$ -galactosidase and hence is an antigenic fused polypeptide. No reaction was observed with a similar large  $\beta$ -galactosidase containing polypeptide in the antigen-negative clone C9 (Fig. 6). Hence this clone expresses a fused polypeptide which is not recognized as an antigen. In other antigen-positive clones, for example clone Ag23 in Fig. 6, the large polypeptide reacted and in addition there was a smear of smaller, presumably degraded material. This polypeptide is apparently unstable in E. coli RY1082, even though this strain contains the  $\text{lon}^-$  mutant which reduced degradation.

In a third class of clones, no reactive polypeptides were demonstrable with immune human IgG. This may be the result of extensive degradation, or may reflect inability of the polypeptide to retain



antigenicity after boiling in NaDodSO<sub>4</sub>. We cannot rule out the possibility that these latter clones are false-positives in the colony screening system.

**EXAMPLE 2      The Production of P.falciparum S**  
**antigens by Recombinant DNA Technology.**

Of 78 antigen-positive E.coli colonies produced as described above and initially examined, one (Ag16) contained a large, particularly abundant fusion protein.

### Isolation of fusion protein from clone Aq16

15        E.coli lysogenic for the Amp<sup>3</sup>-Ag16 recombinant  
phage were grown in L-broth up to a density of  
OD<sub>600</sub> = 0.6 at a temperature of 30°. The phage was  
induced by incubating the cultures at 45° for 15 min.  
Following this induction the cultures were incubated  
20        for a further 90 min at 39° and the bacteria were then  
harvested by centrifugation for 10 min at 3,000 x g.

Bacteria harvested from 1 litre cultures were resuspended in 20 ml Tris-buffer (10 mM Tris-HCl, pH 8.0, 2 mM EDTA, 50 mM NaCl) and lysed by the addition of 0.25 mg/ml lysozyme and incubating for 30 min. To the bacterial lysate was added Triton X-100 (final concentration 0.2%), an equal volume of Tris buffer, containing 20 mM  $MgCl_2$  and 1  $\mu g/ml$  DNase (Deoxyribonuclease, Grade I, Boehringer Mannheim, FRG). After incubating at room temperature for 10 min cell debris was pelleted by centrifugation at 4,000 x g. The 4,000 x g supernatant was then



centrifuged for 30 min at 40,000 x g to sediment the insoluble fusion protein together with other particulate material. The pellet was solubilised in 5 ml of 0.1 M NaPO<sub>4</sub> buffer, pH 6.4, containing 2% sodium dodecyl sulphate (SDS) and 10 mM dithiothreitol (DTT) by boiling for 2 min and loaded on to a column of Sepharose CL6B (Pharmacia, Uppsala, Sweden) which was equilibrated and eluted with 0.2 M NaPO<sub>4</sub> buffer, pH 6.4 containing 0.1% SDS and 1 mM DTT. Aliquots of the fractions eluting from the Sepharose column were examined by 1-dimensional SDS polyacrylamide gel electrophoresis (PAGE). Those containing the fusion protein were pooled, desalted by passage over a PD10 dialysing column (Pharmacia) equilibrated with 1 mM β-mercaptoethanol in H<sub>2</sub>O and freeze dried.

#### Preparation of Antisera

Rabbits were injected subcutaneously and intramuscularly with freeze dried fusion protein (0.5 mg) suspended in 1 ml phosphate buffered saline (PBS) and emulsified in an equal volume of Freund's complete adjuvant. The rabbits received a second injection 4 weeks later with 0.5 mg of the same antigen emulsified in Freund's incomplete adjuvant and were bled for antiserum 2 weeks later.

Antisera were also raised in mice. In this case the bacteria from approximately 1 ml. of an induced culture were lysed in phosphate buffered saline by 4 cycles of freezing and thawing, emulsified in an equal volume of Freund's complete adjuvant and injected intraperitoneally and subcutaneously into female



BALB/c mice. The mice received a second injection 4 weeks later with the same amount of bacterial lysate without added adjuvant, and subsequently bled for antiserum.

5

#### Immunoblotting (Western Blotting)

Antigens released into the culture medium by P.falciparum isolates growing in vitro were  
10 fractionated on one-dimensional SDS-polyacrylamide gels (SDS-PAGE), electrophoretically transferred to nitrocellulose and probed with antibodies raised against the fusion protein or PNG serum essentially using the procedures described by Burnette W.N., 1981,  
15 Analyt. Biochem. 112, pp 195-203.

#### Immunofluorescence

Antiserum raised against the fusion protein  
20 isolated from clone Ag16 (rabbit anti-Ag16 serum) was tested for reactivity against P.falciparum isolate FC27 by using the procedure of indirect immunofluorescence. Air dried, thin smears of parasitized red blood cells were fixed in  
25 acetone/methanol (90:40, v:v) for 15 min at room temperature. The dried smears were reacted with appropriately diluted (1:100 to 1:1000) rabbit anti-Ag16 serum for 30 min at room temperature. After  
30 three 15 min washes in PBS the smears were incubated with a 1:40 dilution of fluorescein-conjugated sheep anti rabbit immunoglobulin for 30 min at room temperature. After three 15 min washes in PBS the slides were flooded with 90% glycerol and then



examined under a microscope using ultraviolet illumination.

#### Nucleic Acid Sequencing

5

The cDNA insert of clone Ag16 was subcloned into the phage vector M13.mp9 (Messing J., Crea R., and Seeburg P.H. 1981, Nucl. Acids. Res., 9, pp 209-321), and sequenced according to the dideoxynucleotide chain termination method (Sanger F., Coulson A.R., Barrell B.G., Smith A.J.H., and Roe B.A., 1980, J. Mol. Biol., 143, pp 167-178).

10

#### RESULTS AND DISCUSSION

15

##### Characterisation of Clone Ag16

20

Using the procedures described in Example 1, clone Ag16 was identified as an antigen-positive E.coli colony which contained an abundant large fusion protein. The recombinant phage  $\lambda$ Amp 3-Ag16 contains a P.falciparum cDNA insert of 830 base pairs. The base sequence of clone Ag16 is shown in Fig.1 and indicates that the antigen coded for by this partial polynucleotide sequence has a homologous repeat structure of 11 amino acids tandemly repeated 23 times.

25

##### Isolation of Ag16 Fusion Protein

30

This fusion protein was insoluble and could be enriched for by lysing induced organisms and centrifuging down insoluble material. This pellet was



solubilized by heating in a buffer containing 2% SDS and 10 mM DTT and a single passage over a Sepharose CL6B gel filtration column provided fusion protein free of the majority of proteins in the original E.coli lysate (Fig.7).

Clone Ag16 corresponds to the S Antigen of P.falciparum FC27.

10 A rabbit immunized with the semi-purified fusion protein obtained from clone Ag16 produced antibodies that reacted with clone Ag16 and not other E.coli colonies containing either other recombinant bacteriophage or the non-recombinant phage  $\lambda$ Amp 3  
15 (Fig.8). Thus this fusion protein induced an antibody response primarily directed against determinants expressed in the P.falciparum portion of the protein.

Conclusive evidence that the Ag16 clone  
20 corresponded to a portion of the isolate FC27 S antigen was obtained by Western blotting experiments. Isolate FC27 has an S antigen (Mr 220,000) which is the dominant antigen detected when culture supernatants are analysed by the Western blotting  
25 procedure using selected sera from naturally immune Papua New Guineans. One clonal population (E12) of P.falciparum derived from isolate FC27 by limit dilution culture expresses a larger but antigenically related S antigen (Mr approximately 250,000). When  
30 equivalent culture supernatants were analysed by the Western blotting procedure using anti-Ag16 serum as the probe the S antigens of isolate FC27 and clone E12 were the only antigens detected (Fig.9).



Association of the Antigen with Mature Parasites

Anti-Agl6 serum was used in indirect immunofluorescence experiments to demonstrate that the corresponding antigen in isolate FC27 was associated with mature asexual stages in the red blood cell. The staining pattern (Fig.10) in which the merozoites inside the segmented schizont were clearly outlined is consistent with the S antigen being located within the parasitophorous vacuole and perhaps also on the merozoite surface.

EXAMPLE 3      The Production of Other Natural Malaria Immunogens.

15

The processes used in Example 1 for preparing recombinant bacteria phage and for selecting E.coli clones making malaria antigens, and in Example 2 for characterising one clone with respect to the parasite antigen it corresponds, to were repeated so as to identify clones producing other antigens of P.falciparum.

20

Results

25

Available nucleotide sequence data on one of these additional clones is given in Figure 2. Information concerning the molecular weight, stage and strain specificity and ultrastructural localisation of these antigens is given in Figures 11-14 and in Tables 1 - 4.

30





38

Table 1.

Molecular Weight of P.falciparum (Isolate FC27) Proteins  
Corresponding to Antigen-Positive Clones

Clone	Molecular Weight *
Ag 7	155,000 & 210,000
Ag 13	155,000 & 210,000
Ag 23	120,000 §
Ag 63	75,000
Ag 144	112,000

\* Molecular weights are approximate as they were determined by the electrophoretic mobility of the proteins on sodium dodecyl sulphate polyacrylamide gels relative to the mobility of proteins of known size and should be more appropriately referred to as relative molecular mass (Mr).

§ An antigenically cross-reactive protein is present in isolates K-1 (Thailand) and NF7 (Ghana) but differs slightly in size. The K-1 antigen is Mr  $\approx$ 127,000 and the NF7 antigen is Mr  $\approx$ 118,000.



Table 2.

Stage Specificity of P.falciparum (Isolate FC27) Proteins Corresponding to Antigen-Positive Clones

	Ring	Trophozoite	Schizont
Ag 7	+	-	+
Ag 13	+	-	+
Ag 23	-	+	+
Ag 63	+	-	+
Ag 144	ND *	ND	ND

\* ND = Not done

Table 3.

Isolate Specificity of P.falciparum Proteins Corresponding to Antigen-Positive Clones

	FC27	K-1	NF7
Ag 7	+	+	+
Ag 13	+	+	+
Ag 23 *	+	+	+
Ag 63	+	+	+
Ag 144	+	+	+

\* Ag 23 varies in apparent MW in the 3 isolates (see Table 1).



Table 4

Patterns of Immunofluorescent Staining Seen with Antisera  
Raised to Antigen-Positive Clones.\*

- 
- Ag 7 The antigen is located on the surface of cells infected with ring-stage (immature) parasites. Some staining was also evident in mature schizont-infected cells.
- Ag 13 Essentially the same staining pattern as for Ag 7. In some cases the antigen appeared to be evenly distributed over the surface of erythrocytes infected with ring stages. In other erythrocytes, also infected with ring stages, patches of more intense fluorescence were evident. Surface location of Ag 13 was demonstrated by reacting serum with intact cells. Antiserum bound only to the surface of infected cells.
- Ag 23 Late trophozoites and schizonts expressed this antigen. Fluorescence of trophozoites was associated with a large number of "speckles" distributed over the entire parasitized cell. There were often two small circular areas of more intense fluorescence, especially seen in the late trophozoite/early schizont. At the late schizont stage, intense fluorescence was seen over the whole parasitized cell.
- Ag 63 An antiserum to Ag 63 reacted predominantly with cells infected with mature parasites (cells containing malaria pigment). Staining was evident around the pigment and over the entire parasite or as a network round developing merozoites. Weaker staining was evident with very immature parasites where a ring of fluorescence surrounded the parasite within the red cell.
- Ag 144 Only mature parasites were stained. Fluorescence was visible either over the whole parasite, or as patches or as a network of fluorescence outlining the segmented schizont.
- 

\* The indirect immunofluorescent antibody procedure was used in each case. Primary antisera were derived from rabbits or mice. The secondary reagents used were FITC-conjugated sheep anti-mouse immunoglobulin or FITC-conjugated sheep anti-rabbit immunoglobulin. Parasitized cells fixed to glass slides were used as antigens.



## CLAIMS:

1. A DNA molecule comprising a nucleotide sequence substantially corresponding to all or a portion of P.falciparum RNA.
2. A DNA molecule according to claim 1, wherein said nucleotide sequence codes for at least one polypeptide of P.falciparum.
3. A DNA molecule according to claim 2, wherein said nucleotide sequence codes for all or a portion of at least two polypeptides of P.falciparum, said polypeptides being derived from one or more isolates, strains or variants of P.falciparum.
4. A DNA molecule according to claim 1, wherein said nucleotide sequence codes for a polypeptide of P.falciparum which substantially corresponds to an S antigen of P.falciparum.
5. A DNA molecule according to claim 1, wherein said nucleotide sequence is characterised by at least a portion thereof comprising a partial base sequence substantially as shown in of Figure 1.
6. A DNA molecule according to claim 1, wherein said nucleotide sequence is characterised by at least a portion thereof comprising a partial base sequence substantially as shown in Figure 2.
7. A DNA molecule comprising a nucleotide sequence capable of being expressed as at least one



polypeptide displaying the antigenicity of a P.falciparum antigen.

8. A recombinant DNA molecule comprising a nucleotide sequence according to any one of claims 1 to 7, operatively linked to an expression control sequence.

9. A recombinant DNA molecule according to claim 8, wherein the expression control sequence includes promoter sequences and initiator sequences, and wherein said nucleotide sequence is located 3' to the promoter and initiator sequences.

10. A recombinant DNA cloning vehicle or vector capable of expressing all or part of at least one polypeptide or protein of P.falciparum, and having inserted therein a nucleotide sequence according to any one of claims 1 to 7, said sequence being operatively linked to an expression control sequence.

11. A recombinant DNA cloning vehicle according to claim 10, wherein the expression control sequence includes promoter sequences and initiator sequences, and wherein said nucleotide sequence is located 3' to the promoter and initiator sequences.

12. A recombinant DNA cloning vehicle according to claim 10, characterised in that said nucleotide sequence and said expression control sequence are inserted into a bacteriophage.



13. A recombinant DNA cloning vehicle according to claim 12, characterised in that said bacteriophage is bacteriophage Amp 3.

14. A host cell containing a recombinant DNA molecule according to claim 8, or a recombinant DNA cloning vehicle or vector according to claim 10.

15. A synthetic peptide or polypeptide displaying the antigenicity of all or a portion of at least one P.falciparum antigen.

16. A synthetic peptide or polypeptide according to claim 15, characterised in that it displays the antigenicity of all or a portion of an S antigen of P.falciparum.

17. A synthetic peptide or polypeptide according to claim 15, characterised in that it substantially corresponds to all or a portion of one of the antigens characterised in Figures 7 to 14 and in Tables 1 to 4.

18. A fused polypeptide comprising a polypeptide sequence displaying the antigenicity of a P.falciparum antigen as the C-terminal sequence, and an additional polypeptide as the N-terminal sequence fused thereto.

19. A fused polypeptide according to claim 18, wherein the additional polypeptide is a polypeptide coded for by the DNA of a recombinant DNA cloning vehicle or vector.



20. A method of producing a fused polypeptide according to claim 18, which comprises the steps of culturing a host cell according to claim 14, and recovering said fused polypeptide from the culture.
21. A fused polypeptide produced by the method of claim 20.
22. A method of producing a polypeptide according to claim 15, which comprises the steps of cleaving a fused polypeptide according to claim 21, and separating said desired polypeptide from said additional polypeptide.
23. A polypeptide produced by the method of claim 22.
24. A composition for stimulating immune responses against P.falciparum antigens in a mammal, comprising at least one polypeptide displaying the antigenicity of a P.falciparum antigen, together with a pharmaceutically acceptable carrier therefor.
25. A composition according to claim 24, further comprising an adjuvant.
26. A composition for stimulating immune responses against P.falciparum antigens in a mammal, comprising a virus or microorganism in association with a pharmaceutically acceptable carrier, the virus or microorganism having inserted therein a DNA molecule comprising a nucleotide sequence capable of



being expressed at least one polypeptide displaying the antigenicity of a P.falciparum antigen.

27. A method of stimulating immune responses against P.falciparum antigens in a mammal, which comprises administering a composition according to claim 24 to said mammal.





1/14

## NUCLEOTIDE AND CORRESPONDING AMINO ACID SEQUENCE OF CLONE Ag 16

Glu Phe Arg Pro Ala Lys Ala Ser Gln Gly Gly Leu Glu Asp  
GAA TTC CGT CCC GCA AAG GCT AGT CAA GGAGGATTA GAA GAT

LINKER

2	T	A	T	A
3	C	G	T	A
4	T	A	T	A
5	T	A	T	T
6	T	A	T	A
7	T	A	T	T
8	T	G	A	A
9	T	A	T	T
10	T	A	T	A
11	T	A	T	T
12	T	A	T	T
13	C	G	T	T
14	T	A	T	T
15	C	G	T	A
16	T	A	T	A
17	T	A	T	T
18	T	A	A	A
19	T	A	A	A
20	T	G	A	A
21	T	A	A	A
22	T	A	A	T

23 CCT GCA AAA GCT AGT CAA GGA GGATTA GAA GAT CCT CGG AAT TC  
 LINKER

Fig. 1.

2/14

PARTIAL NUCLEOTIDE AND CORRESPONDING AMINO ACID  
SEQUENCE OF CLONE Ag 13\*

Glu	Phe	Arg	Lys	Ile	Asn	Thr	Glu	Met
GAA	TTC	CGC	AAA	ATT	AAT	ACA	GAA	ATG
10								
Lys	Asn	Gln	Asn	Glu	Asn	Val	Pro	Glu
AAA	AAC	CAA	AAT	GAA	AAT	GTA	CCA	GAA
20								
His	Val	Gln	His	Asn				
CAT	GTA	CAA	CAT	AAT				
							30	
	Ala	Glu	Glu	Asn	Val	Glu	His	Asp
	GCT	GAA	GAA	AAT	GTA	GAA	CAT	GAT
	Ala	Glu	Glu	Asn	Val	Glu	His	Asp
	GCT	GAA	GAA	AAT	GTA	GAA	CAT	GAT
40								
	Ala	Glu	Glu	Asn	Val	Glu	His	Asp
	GCT	GAA	GAA	AAT	GTA	GAA	CAT	GAT
		50						
	Ala	Glu	Glu	Asn	Val	Glu	His	Asp
	GCT	GAA	GAA	AAT	GTA	GAA	CAT	GAT
					60			
	Ala	Glu	Glu	Asn	Val	Glu	His	Asp
	GCT	GAA	GAA	AAT	GTA	GAA	CAT	GAT
	Ala	Glu	Glu	Asn	Val			
	GCT	GAA	GAA	AAT	GTA			
		70						
		Glu	Glu	Asn	Val			
		GAA	GAA	AAT	GTT			
		Glu	Glu	Val				
		GAA	GAA	GTA				
		Glu	Glu	Asn	Val			
		GAA	GAA	AAT	GTA			
		80						
		Glu	Glu	Asn	Val			
		GAA	GAA	AAT	GTA			

FIG. 2A.

SUBSTITUTE SHEET



3/14

Glu	Glu	Asn	Val
GAA	GAA	AAT	GTA

90

Glu	Glu	Asn	Val
GAA	GAA	AAT	GTT

Glu	Glu	Val
GAA	GAA	GTA

Glu	Glu	Asn	Val
GAA	GAA	AAT	GTA

100

Glu	Glu	Asn	Val
GAA	GAA	AAT	GTA

Glu	Glu	Asn	Val
GAA	GAA	AAT	GTA

110

Glu	Glu	Asn	Val
GAA	GAA	AAT	GTT

Glu	Glu	Asn	Val
GAA	GAA	AAT	GTT

Glu	Glu	Asn	Val
GAA	GAA	AAT	GTT

120

Glu	Glu	Asn	Val
GAA	GAA	AAT	GTA

Glu	Glu	Asn	Val
GAA	GAA	AAT	GTA

120

Glu	Glu	Asn
GAA	GAA	AAT

\*THIS SEQUENCE COMPRISES THE FIRST 389 BASES FROM THE 5' END OF THE cDNA INSERT IN CLONE Ag 13.

Fig. 2B.



4/14



CONSTRUCTION OF AN EXPRESSION LIBRARY FROM *P.falciparum* mRNA

FIG.3.

5/14

DETECTION OF CLONES EXPRESSING P. FALCIPARUM ANTIGENS

- A PRIMARY SCREEN WITH IMMUNE SERUM
- B PRIMARY SCREEN WITH NON-IMMUNE SERUM
- C SECONDARY SCREEN WITH IMMUNE SERUM
- D SECONDARY SCREEN WITH NON-IMMUNE SERUM

*Fig.4.*

SUBSTITUTE SHEET




6/14

CLONES EXPRESSING P. FALCIPARUM ANTIGENS AND HYBRIDIZING  
WITH P. FALCIPARUM cDNA

anti-*P.falcip.*

cDNA

*Fig. 5.*

7/14

# ELECTROPHONETIC ANALYSIS OF ANTIGEN-POSITIVE CLONES




FIG.6.

8/14

ISOLATION OF FUSED POLYPEPTIDE FROM CLONE AG 16



Fig. 7.

COLONY IMMUNOASSAY WITH ANTISERA AGAINST POLYPEPTIDE FROM CLONE AG 16





Fig. 8.





9/14


DETECTION OF S. ANTIGEN WITH ANTISERA AGAINST  
FUSED POLYPEPTIDE FROM CLONE AG 16



**Fig.9**

10/14


IMMUNOFLUORESCENT STAINING OF P. FALCIPARUM WITH ANTISERUM  
TO CLONE AG 16



*Fig. 10.*

11/14


IMMUNOFLUORESCENT STAINING OF P. FALCIPARUM WITH ANTISERUM  
TO CLONE AG 13.



*Fig. 11.*

12/14


IMMUNOFLUORESCENT STAINING OF P. FALCIPARUM WITH ANTISERUM  
TO CLONE AG 23



*FIG.12.*

13/14


IMMUNOFLUORESCENT STAINING OF P. FALCIPARUM WITH ANTISERUM  
TO CLONE AG63



*Fig.13.*

14/14

IMMUNOFLUORESCENT STAINING OF P. FALCIPARUM WITH ANTISERUM  
TO CLONE AG 144



*FIG. 14.*

# INTERNATIONAL SEARCH REPORT

International Application No PCT/AU 84/00016

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int. Cl. <sup>3</sup> C12N 15/00, C07G 17/00, C12P 19/34, 21/00, 21/02, A61K 39/015		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched *		
Classification System	Classification Symbols	
IPC	C07G 17/00, C12P 19/34, 21/00, 21/02 A61K 39/015, C12N 15/00	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched *		
AU: IPC as above		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT</b> <sup>14</sup>		
Category *	Citation of Document, <sup>15</sup> with indication, where appropriate, of the relevant passages <sup>17</sup>	Relevant to Claim No. <sup>18</sup>
X	GB, A, 2096893 (THE WELLCOME FOUNDATION LTD.) 27 October 1982 (27.10.82)	(1-7)
X	GB, A, 2099300 (THE WELLCOME FOUNDATION LTD.) 8 December 1982 (08.12.82)	(24-27)
A	JP, A, 57-156421 (NIHON KOUTAI KENKYUSHO K.K.) 27 September 1982 (27.09.82) (JAPATIC English Language Abstract)	
A	EP, A2, 0047485 (BEHRINGWERKE AG.) 17 March 1982 (17.03.82)	
A	CH, A5, 575467 (TAKEDA CHEMICAL INDUSTRIES) 14 May 1976 (14.05.76)	
A	DE, A, 2304780 (TAKEDA CHEMICAL INDUSTRIES LTD.) 9 August 1973 (09.08.73)	
P	WO, A, 83/02896 (D <sup>1</sup> ANTONIO) 1 September 1983 (01.09.83)	(1-7)
P	WO, A, 83/04370 (MUNCHENER APPARATEBAU FUR ELEKTRO- NISCHE GERÄTE KIMMEL GMBH) 22 December 1983 (22.12.83)	(24-27)
<p>* Special categories of cited documents: <sup>16</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search *	Date of Mailing of this International Search Report *	
30 April 1984 (30.04.84)	2 May 1984	
International Searching Authority *	Signature of Authorized Officer <sup>20</sup>	
Australian Patent Office	A.S. Moore <i>A.A. Moore</i>	

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON  
INTERNATIONAL APPLICATION NO. PCT/AU 84/00016

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Members			
GB	2096893	AU 82593/82 JP 58010524	EP 62924 ZA 822539	IL 65496 ZW 7282	
GB	2099300	AU 83875/82 JP 57197222	EP 71705 ZA 823555	IL 65835 ZW 10682	
JP	57156421				
EP	47485	AR 226477 IL 63764	AU 75049/81 JP 57083278	DE 3033776 ZA 816215	
CH	575467	BE 794975 FR 2181710 NL 7301822	CA 994692 GB 1414696 US 4014860	DE 2304780 JP 48082089	
DE	2304780	BE 794975 FR 2181710 NL 7301822	CA 994692 GB 1414696 US 4014860	CH 575467 JP 48082089	
WO	8302896	AU 13766/83	EP 101505		
WO	8304370	AU 16067/83	DE 3221881	EP 96422	

END OF ANNEX